Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular, fibrosis and neuroscience. Our employees work every day to transform patients’ lives through science. Celgene and Juno Therapeutics are wholly owned subsidiaries of Bristol Myers Squibb company. In certain countries outside the U.S., due to local laws, Celgene and Juno Therapeutics are referred to as, Celgene, a Bristol Myers Squibb company and Juno Therapeutics, a Bristol Myers Squibb company.

BMS-Sponsor-of-KCRS20-by-KidneyCAN

Bristol Myers Squibb Pipeline

Committed to Patients. Driven to Discover.

At Bristol Myers Squibb, we are driven by the discovery of science that may transform the lives of cancer patients.

Until we can meet again, please explore our oncology and hematology pipeline:

Investigational Trials
With Bristol Myers Squibb Immuno-Oncology Agents

Click here to view or download full-size PDF.

KidneyCAN thanks Bristol Myers Squibb for their generous support of KCRS21 as a Sustaining Partner.

KidneyCAN Platinum Guidestar Seal

KidneyCAN is a registered 501(c)(3) nonprofit grassroots organization dedicated to funding and finding a cure for kidney cancer.

Contact KidneyCAN

KidneyCAN, 8327 Germantown Avenue, Philadelphia, PA 19118